Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
10 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 43(4); December 2011
Prev issue Next issue
Review Article
Systems Biology Approaches to Decoding the Genome of Liver Cancer
Ju-Seog Lee, Ji Hoon Kim, Yun-Yong Park, Gordon B. Mills
Cancer Res Treat. 2011;43(4):205-211.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.205
AbstractAbstract PDFPubReaderePub
Molecular classification of cancers has been significantly improved patient outcomes through the implementation of treatment protocols tailored to the abnormalities present in each patient's cancer cells. Breast cancer represents the poster child with marked improvements in outcome occurring due to the implementation of targeted therapies for estrogen receptor or human epidermal growth factor receptor-2 positive breast cancers. Important subtypes with characteristic molecular features as potential therapeutic targets are likely to exist for all tumor lineages including hepatocellular carcinoma (HCC) but have yet to be discovered and validated as targets. Because each tumor accumulates hundreds or thousands of genomic and epigenetic alterations of critical genes, it is challenging to identify and validate candidate tumor aberrations as therapeutic targets or biomarkers that predict prognosis or response to therapy. Therefore, there is an urgent need to devise new experimental and analytical strategies to overcome this problem. Systems biology approaches integrating multiple data sets and technologies analyzing patient tissues holds great promise for the identification of novel therapeutic targets and linked predictive biomarkers allowing implementation of personalized medicine for HCC patients.

Citations

Citations to this article as recorded by  
  • Systems Challenges of Hepatic Carcinomas: A Review
    Dhatri Madduru, Johny Ijaq, Sujata Dhar, Saumyadip Sarkar, Naresh Poondla, Partha S. Das, Silvia Vasquez, Prashanth Suravajhala
    Journal of Clinical and Experimental Hepatology.2019; 9(2): 233.     CrossRef
  • Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease
    Yuan Tian, Vincent Wai-Sun Wong, Henry Lik-Yuen Chan, Alfred Sze-Lok Cheng
    Seminars in Cancer Biology.2013; 23(6): 471.     CrossRef
  • The Impact of Network Medicine in Gastroenterology and Hepatology
    György Baffy
    Clinical Gastroenterology and Hepatology.2013; 11(10): 1240.     CrossRef
  • 9,944 View
  • 64 Download
  • 3 Crossref
Close layer
Original Articles
Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment
Dal Yong Kim, Dae Ho Lee, Sun-Joo Jang, Sang-We Kim, Cheolwon Suh, Jung Shin Lee
Cancer Res Treat. 2011;43(4):212-216.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.212
AbstractAbstract PDFPubReaderePub
PURPOSE
This study was designed to evaluate the efficacy of a combination treatment of S-1 plus either irinotecan or docetaxel for advanced/metastatic non-small cell lung cancer (NSCLC) patients who have already failed 3 or more lines of treatment.
MATERIALS AND METHODS
This was a prospective single center phase II study. The eligible patients received S-1 40 mg/m2 twice a day orally on days 1 though 14 combined with irinotecan 150 mg/m2on D1 only or docetaxel 35 mg/m2 on D1 and D8. The treatment was repeated every 3 weeks until disease progression, unacceptable toxicity, or patient refusal. The choice between the two regimens was made at the discretion of the treating physician.
RESULTS
A total of 14 patients participated in the study. There were 3 patients with squamous cell carcinoma, 9 with adenocarcinoma, and 2 with NSCLC, NOS. Eight of the patients were male. There were 8 patients with an Eastern Cooperative Oncology Group (ECOG) of 1, and 6 patients with an ECOG of 2. All the patients had already been treated with platinum-based chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitor therapy. Out of the 14 patients, 10 received irinotecan and S-1 and the other 4 received docetaxel and S-1. Twelve patients had also received pemetrexed. Disappointingly, there were no response from 2 patients with a stable disease, and therefore, as per the protocol, we stopped the study early. With a median follow-up time of 49 months, the median survival time was 5.6 months (95% confidence interval, 4.3 to 6.9 months).
CONCLUSION
S-1 containing doublets did not show activity in this population as a salvage treatment and further investigation cannot be recommended.

Citations

Citations to this article as recorded by  
  • Docetaxel Nanotechnology in Anticancer Therapy
    Pengxiang Zhao, Didier Astruc
    ChemMedChem.2012; 7(6): 952.     CrossRef
  • 9,141 View
  • 47 Download
  • 1 Crossref
Close layer
Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis
Sang Hoon Chun, Ji Eun Lee, Mi Hee Park, Jin-Hyoung Kang, Young Kyoon Kim, Young-Pil Wang, Jae Kil Park, Hoon-Kyo Kim
Cancer Res Treat. 2011;43(4):217-224.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.217
AbstractAbstract PDFPubReaderePub
PURPOSE
This study aimed to analyze the efficacy and toxicity of gemcitabine plus platinum chemotherapy for patients aged 70 years or older with advanced non-small-cell lung cancer (NSCLC).
MATERIALS AND METHODS
We reviewed the records of stage IIIB, IV NSCLC patients or surgically inoperable stage II, IIIA NSCLC patients who were aged 70 years or older when treated with gemcitabine (1,250 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) chemotherapy from 2001 to 2010 at Seoul St. Mary's Hospital, Uijeongbu St. Mary's Hospital and St. Vincent's Hospital. Gemcitabine was administered on days 1 and 8, and cisplatin or carboplatin was administered on day 1. Treatments were repeated every 3 weeks for a maximum of 4 cycles.
RESULTS
The median age of the 62 patients was 73.5 years (range, 70 to 84 years). Forty-one (66%) patients exhibited comorbidity. The mean number of treatment cycles was 3.9. The compared average relative dose intensity of gemcitabine plus platinum chemotherapy was 84.8%. The median progression-free survival and overall survival (OS) were 5.0 months and 9.4 months, respectively. Reduced Eastern Cooperative Oncology Group (ECOG) performance status (none vs. > or =1) and weight loss (<5% vs. > or =5%) after treatment were found to have a significant effect on OS (p=0.01).
CONCLUSION
Gemcitabine plus platinum chemotherapy is an effective treatment option with an acceptable level of toxicity in patients aged 70 years or older with good performance status in advanced NSCLC.

Citations

Citations to this article as recorded by  
  • Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
    Xue-Song Sun, Xiao-Hao Wang, Sai-Lan Liu, Dong-Hua Luo, Rui Sun, Li-Ting Liu, Shan-Shan Guo, Qiu-Yan Chen, Lin-Quan Tang, Hai-Qiang Mai
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer
    Yui Tomita, Toshiaki Saito, Masao Okadome, Takako Eto, Kazuya Ariyoshi, Kumi Shimamoto
    International Journal of Clinical Oncology.2014; 19(4): 662.     CrossRef
  • A cross-country review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies
    Anna De Geer, Jennifer Eriksson, Henrik W. Finnern
    Journal of Medical Economics.2013; 16(1): 134.     CrossRef
  • Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
    Anandi Sawant, Jessy Deshane, Joel Jules, Carnella M. Lee, Brittney A. Harris, Xu Feng, Selvarangan Ponnazhagan
    Cancer Research.2013; 73(2): 672.     CrossRef
  • Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways
    Anandi Sawant, Cara C. Schafer, Tong Huan Jin, Jaroslaw Zmijewski, Hubert M. Tse, Justin Roth, Zhihuan Sun, Gene P. Siegal, Victor J. Thannickal, Stefan C. Grant, Selvarangan Ponnazhagan, Jessy S. Deshane
    Cancer Research.2013; 73(22): 6609.     CrossRef
  • 11,133 View
  • 63 Download
  • 5 Crossref
Close layer
A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis
Dong Hyun Lee, Sung Yong Oh, Yu Rim Lee, Seok Jae Huh, Hyun Hwa Yoon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Young Kim, Hyo-Jin Kim, Hyuk-Chan Kwon
Cancer Res Treat. 2011;43(4):225-230.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.225
AbstractAbstract PDFPubReaderePub
PURPOSE
Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) is common and is the second most common cause of death. Clinical studies regarding chemotherapy for CRC with PC have been classically rather limited in scope. We evaluated the efficacy of modified oxaliplatin, leucovorin, and fluorouracil (m-FOLFOX4) regimen for PC of CRC origin.
MATERIALS AND METHODS
CRC patients with PC were treated with cycles of oxaliplatin at 85 mg/m2 on day 1, leucovorin 20 mg/m2 followed by 5-fluorouracil (5-FU) via a 400 mg/m2 bolus and a 22 hours continuous infusion of 600 mg/m2 5-FU on days 1-2 at 2-week intervals.
RESULTS
Forty patients participated in this study. Median age was 55 years. Thirty-two patients (80.0%) received previous operation, and 60.0% of PC occurred synchronously. Thirty-five patients (87.5%) were assessable and exhibited measurable lesions. Two patients (5.7%) demonstrated complete response and five patients (14.3%) showed partial response. The median time to progression was 4.4 months (95% confidence interval, 2.5 to 6.3 months), the median overall survival time was 21.5 months (95% confidence interval, 17.2 to 25.7 months). There was no treatment related death. Presence of liver metastasis (p=0.022), performance status (p=0.039), and carcinoembryonic antigen level (p=0.016) were related to the time to progression. Patients with low carcinoembryonic antigen level (37.2 months vs. 15.6 months, p=0.001) or good performance status (22.5 months vs. 6.8 months, p=0.040) showed better overall survival.
CONCLUSION
The m-FOLFOX4 regimen was determined to be effective for CRC patients with PC.

Citations

Citations to this article as recorded by  
  • Review of systemic chemotherapy in unresectable colorectal peritoneal carcinomatosis
    Udit Nindra, Adel Shahnam, Kate L. Mahon
    Asia-Pacific Journal of Clinical Oncology.2022; 18(1): 7.     CrossRef
  • Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial
    Gabriel Glockzin, Florian Zeman, Roland S. Croner, Alfred Königsrainer, Jörg Pelz, Michael A. Ströhlein, Beate Rau, Dirk Arnold, Michael Koller, Hans J. Schlitt, Pompiliu Piso
    Clinical Colorectal Cancer.2018; 17(4): 285.     CrossRef
  • Treatment of peritoneal metastases from small bowel adenocarcinoma
    Koen P. Rovers, Eelco de Bree, Yutaka Yonemura, Ignace H. de Hingh
    International Journal of Hyperthermia.2017; 33(5): 571.     CrossRef
  • Percutaneous lung ablation of pulmonary recurrence may improve survival in selected patients undergoing cytoreductive surgery for colorectal cancer with peritoneal carcinomatosis
    T.A. Bin Traiki, O.M. Fisher, S.J. Valle, R.N. Parikh, M.A. Kozman, D. Glenn, M. Power, W. Liauw, N.A. Alzahrani, D.L. Morris
    European Journal of Surgical Oncology (EJSO).2017; 43(10): 1939.     CrossRef
  • Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis
    C. Demtröder, W. Solass, J. Zieren, D. Strumberg, U. Giger‐Pabst, M.‐A. Reymond
    Colorectal Disease.2016; 18(4): 364.     CrossRef
  • Therapeutic options for peritoneal metastasis arising from colorectal cancer
    Gabriel Glockzin, Hans J Schlitt, Pompiliu Piso
    World Journal of Gastrointestinal Pharmacology and Therapeutics.2016; 7(3): 343.     CrossRef
  • Challenges in the multidisciplinary management of stage IV colon and rectal cancer
    Pompiliu Piso, Dirk Arnold, Gabriel Glockzin
    Expert Review of Gastroenterology & Hepatology.2015; 9(3): 317.     CrossRef
  • Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis
    Gabriel Glockzin, Michael Gerken, Sven A Lang, Monika Klinkhammer-Schalke, Pompiliu Piso, Hans J Schlitt
    BMC Cancer.2014;[Epub]     CrossRef
  • Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?
    H. Ishida, K. Kumamoto, K. Ishibashi, S. Hatano, T. Matsuzawa, N. Okada, Y. Kumagai, H. Baba, N. Haga
    Techniques in Coloproctology.2013; 17(6): 647.     CrossRef
  • Peritoneal carcinomatosis of colorectal origin: is it really an end-stage disease?
    E. Chouillard, V. Greco, N. Tsiminikakis
    Techniques in Coloproctology.2013; 17(6): 619.     CrossRef
  • Peritoneal carcinomatosis from colorectal cancer: hyperthermic intraperitoneal chemotherapy and the role of systemic chemotherapy
    Michael Michael
    Colorectal Cancer.2013; 2(5): 449.     CrossRef
  • Role of Chemotherapy in Peritoneal Carcinomatosis in Metastatic Colorectal Cancer
    Jan Franko, Charles D. Goldman, Kiran K. Turaga
    Current Colorectal Cancer Reports.2013; 9(3): 242.     CrossRef
  • A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial
    Gabriel Glockzin, Justine Rochon, Dirk Arnold, Sven A Lang, Frank Klebl, Florian Zeman, Michael Koller, Hans J Schlitt, Pompiliu Piso
    BMC Cancer.2013;[Epub]     CrossRef
  • A Long Survived Case of Transverse Colon Cancer with Peritoneal Dissemination Treated by Multidisciplinary Treatment Including Hyperthermic Intraperitoneal Chemotherapy
    Toshiyuki Nakazawa, Takanori Goi, Mituhiro Morikawa, Kenji Koneri, Makoto Murakami, Yasuo Hirono, Atushi Iida, Kanji Katayama, Akio Yamaguchi, Atomu Murai
    Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons).2012; 37(6): 1136.     CrossRef
  • 11,590 View
  • 62 Download
  • 14 Crossref
Close layer
Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective Study
Paulo Rodrigues, Flavio O. Hering, Alex Meller
Cancer Res Treat. 2011;43(4):231-235.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.231
AbstractAbstract PDFPubReaderePub
PURPOSE
High-risk prostate cancer patients undergoing treatment often experience biochemical recurrence. The use of bisphosphonates as an adjuvant treatment delays skeletal events, yet whether or not bisphosphonates also delay metastastic development remains to be determined.
MATERIALS AND METHODS
A total of 140 high-risk prostate cancer patients who were undergoing definitive treatment and who had clinically organ-confined disease and who suffered from biochemical recurrence were administered intravenous (IV) clodronate. The patients were treated with a radical retropubic prostatectomy (RP) or curative radiotherapy (RTx). Upon androgen deprivation therapy initiation, tri-monthly IV clodronate was added to the treatment to prevent bone demineralization. Twenty-six out of 60 operated cases and 45 out of 80 irradiated cases received bisphosphonate. The length of time until the first bone metastasis was recorded and analyzed.
RESULTS
No statistical difference was found for the type of primary treatment (RP or RTx) on the time to the first bone metastasis (95% confidence interval [CI], 0.40 to 2.43; p=0.98). However, there was a clear advantage favoring the group that received bisphosphonate (p<0.001). The addition of bisphosphonate delayed the appearance of the first bone metastasis by seven-fold (95% CI, 3.1 to 15.4; p<0.001).
CONCLUSION
Treatment with tri-monthly IV clodronate delayed the time to the first bone metastasis in high-risk prostate cancer patients who were experiencing an increase in the prostate specific antigen level after definitive treatment.

Citations

Citations to this article as recorded by  
  • Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer
    Xiangyu Zhang
    Cancer Communications.2019;[Epub]     CrossRef
  • Bone-Targeted Therapies in Cancer-Induced Bone Disease
    Sofia Sousa, Philippe Clézardin
    Calcified Tissue International.2018; 102(2): 227.     CrossRef
  • Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review
    Roderick C.N. van den Bergh, Niels J. van Casteren, Thomas van den Broeck, Eve R. Fordyce, William K.M. Gietzmann, Fiona Stewart, Steven MacLennan, Saeed Dabestani, Joaquim Bellmunt, Michel Bolla, Erik Briers, Philip Cornford, Steven Joniau, Malcolm D. Ma
    European Urology.2016; 69(5): 802.     CrossRef
  • Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies
    Bruno Sainz, Emily Carron, Mireia Vallespinós, Heather L. Machado
    Mediators of Inflammation.2016; 2016: 1.     CrossRef
  • Osteopontin is a useful predictor of bone metastasis and survival in patients with locally advanced nasopharyngeal carcinoma
    Xue Hou, Xuan Wu, Peiyu Huang, Jianhua Zhan, Ting Zhou, Yuxiang Ma, Tao Qin, Rongzhen Luo, Yanfen Feng, Ying Xu, Likun Chen, Li Zhang
    International Journal of Cancer.2015; 137(7): 1672.     CrossRef
  • Recent advances in bone-targeted therapies of metastatic prostate cancer
    Xiyun Deng, Guangchun He, Junwen Liu, Feijun Luo, Xiaoning Peng, Shigang Tang, Zhiyong Gao, Qinlu Lin, Jill M. Keller, Tao Yang, Evan T. Keller
    Cancer Treatment Reviews.2014; 40(6): 730.     CrossRef
  • Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer
    Nicole M Reusser, Heather J Dalton, Sunila Pradeep, Vianey Gonzalez-Villasana, Nicholas B Jennings, Hernan G Vasquez, Yunfei Wen, Rajesh Rupaimoole, Archana S Nagaraja, Kshipra Gharpure, Takahito Miyake, Jie Huang, Wei Hu, Gabriel Lopez-Berestein, Anil K
    Cancer Biology & Therapy.2014; 15(8): 1061.     CrossRef
  • Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells
    R. Thaler, S. Spitzer, H. Karlic, C. Berger, K. Klaushofer, F. Varga
    Biochemical Pharmacology.2013; 85(2): 173.     CrossRef
  • A new bisphosphonate derivative, CP, induces gastric cancer cell apoptosis via activation of the ERK1/2 signaling pathway
    Hai-jun Wang, Yu Liu, Li-qiao Fan, Cai-li Han, Ye Jiang, Shu-jie Cheng, Yong Li
    Acta Pharmacologica Sinica.2013; 34(12): 1535.     CrossRef
  • 9,735 View
  • 51 Download
  • 9 Crossref
Close layer
Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
Ji Soo Park, Jae Yun Lim, Seung Kyo Park, Min Kyung Kim, Hee Sung Ko, Sun Och Yoon, Jong Won Kim, Seung Ho Choi, Jae Yong Cho
Cancer Res Treat. 2011;43(4):236-243.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.236
AbstractAbstract PDFPubReaderePub
PURPOSE
The aims of this study are to find out whether the sequence of chemotherapeutic regimens including second- and third-line taxane and irinotecan influences the survival of patients with unresectable gastric carcinoma and to identify clinical characteristics of patients with improved response.
MATERIALS AND METHODS
Fifty gastric carcinoma patients who were treated by third-line sequential chemotherapy between November 2004 and July 2010 were enrolled in this study. Their overall survival (OS) and time to progression (TTP) were set up as primary and secondary end points. For the sequence of chemotherapy regimen, two arms were used. Arm A was defined as 5-fluorouracil (5-FU)+cisplatin (FP) or folinic acid, 5-FU and oxaliplati (FOLFOX), followed by folinic acid, 5-FU and irinotecan (FOLFIRI), and paclitaxel or docetaxel plus 5-FU, with or without epirubicin. Arm B was defined as FP or FOLFOX, followed by paclitaxel or docetaxel plus 5-FU, and FOLFIRI.
RESULTS
The median OS of all patients was 16.0 months (95% confidence interval, 13.6 to 18.3 months), which is longer than historical control of patients who did not receive third-line chemotherapy. The sequence of second and third-line regimen, including irinotecan and taxane, did not present significant difference in OS or TTP after failure of 5-FU with platinum chemotherapy. In survival analysis of patients' clinicopathologic characteristics, poor prognosis was shown in patients with poorly differentiated histologic features, elevated serum carcinoembryonic level, and shorter TTP of first line chemotherapy.
CONCLUSION
It is possible for patients to respond differently to chemotherapy due to differences in clinical features and underlying gene expression profiles. Development of individualized chemotherapy regimens based on gene expression profiles is warranted.

Citations

Citations to this article as recorded by  
  • Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
    Daniel V.T. Catenacci, Stephanie Moya, Samantha Lomnicki, Leah M. Chase, Bryan F. Peterson, Natalie Reizine, Lindsay Alpert, Namrata Setia, Shu-Yuan Xiao, John Hart, Uzma D. Siddiqui, D. Kyle Hogarth, Oliver S. Eng, Kiran Turaga, Kevin Roggin, Mitchell C.
    Cancer Discovery.2021; 11(2): 308.     CrossRef
  • Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer
    Minkyu Jung, Kyu Hyun Park, Hyun Myong Kim, Tae Soo Kim, Xianglan Zhang, Sun-Mi Park, Seung-Hoon Beom, Hyo Song Kim, Jae-Ho Cheong, Hyun Cheol Chung, John Soong, Shu-chuan Lin, Sun Young Rha
    Gastric Cancer.2019; 22(6): 1153.     CrossRef
  • Advanced gastric cancer: is there an optimal chemotherapy regimen?
    Kalliopi Andrikou, Massimiliano Salati, Annalisa Fontana, Andrea Spallanzani, Stefania Pipitone, Fabio Gelsomino, Monica Barbolini, Stefano Cascinu
    Expert Review of Quality of Life in Cancer Care.2017; 2(2): 123.     CrossRef
  • Third-line chemotherapy in advanced gastric cancer
    Yu Zheng, Xu-Qing Zhu, Xiao-Gang Ren
    Medicine.2017; 96(24): e6884.     CrossRef
  • Melatonin pre-treatment mitigates SHSY-5Y cells against oxaliplatin induced mitochondrial stress and apoptotic cell death
    Mohammad Waseem, Upasana Sahu, Mohd. Salman, Arnab Choudhury, Sudeshna Kar, Heena Tabassum, Suhel Parvez, Saeid Ghavami
    PLOS ONE.2017; 12(7): e0180953.     CrossRef
  • Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
    Valentina Fanotto, Mario Uccello, Irene Pecora, Lorenza Rimassa, Francesco Leone, Gerardo Rosati, Daniele Santini, Riccardo Giampieri, Samantha Di Donato, Gianluca Tomasello, Nicola Silvestris, Filippo Pietrantonio, Francesca Battaglin, Antonio Avallone,
    The Oncologist.2017; 22(12): 1463.     CrossRef
  • Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients
    Lihong Huang, Yongyue Wei, Sipeng Shen, Qianwen Shi, Jianling Bai, Jin Li, Shukui Qin, Hao Yu, Feng Chen
    Oncotarget.2017; 8(17): 29346.     CrossRef
  • Apatinib for the treatment of gastric cancer
    Giandomenico Roviello, Andrea Ravelli, Anna Ida Fiaschi, Maria Rosa Cappelletti, Angela Gobbi, Chiara Senti, Laura Zanotti, Karol Polom, Andrew R. Reynolds, Stephen B. Fox, Daniele Generali
    Expert Review of Gastroenterology & Hepatology.2016; : 1.     CrossRef
  • Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
    Jin Li, Shukui Qin, Jianming Xu, Jianping Xiong, Changping Wu, Yuxian Bai, Wei Liu, Jiandong Tong, Yunpeng Liu, Ruihua Xu, Zhehai Wang, Qiong Wang, Xuenong Ouyang, Yan Yang, Yi Ba, Jun Liang, Xiaoyan Lin, Deyun Luo, Rongsheng Zheng, Xin Wang, Guoping Sun,
    Journal of Clinical Oncology.2016; 34(13): 1448.     CrossRef
  • Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric Cancer
    Sung Chul Park, Hoon Jai Chun
    The Korean Journal of Gastroenterology.2015; 66(1): 1.     CrossRef
  • Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer
    Hye Jung Kwon, Moo In Park, Seun Ja Park, Won Moon, Sung Eun Kim, Hae Won Lee, Youn Jung Choi, Jae Hyun Kim
    The Korean Journal of Gastroenterology.2015; 66(1): 10.     CrossRef
  • Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy
    Vinod Vijay Subhash, Mei Shi Yeo, Woei Loon Tan, Wei Peng Yong
    Journal of Immunology Research.2015; 2015: 1.     CrossRef
  • Impact of the availability of active cytotoxic agents on the survival of patients with advanced gastric cancer
    BYUNG HA CHO, HYE SOOK HAN, JIHYUN KWON, JOUNG-HO HAN, SOON MAN YOON, DAE HOON KIM, HYO YUNG YUN, KI HYEONG LEE, SEI JIN YOUN, SEUNG TAIK KIM
    Oncology Letters.2015; 10(4): 2481.     CrossRef
  • Design of precise third-line therapy for gastric cancer: target or chemotherpy?
    Jae Yong Cho
    The Korean Journal of Internal Medicine.2013; 28(3): 297.     CrossRef
  • Sequential Chemotherapies for Advanced Gastric Cancer: A Retrospective Analysis of 111 Patients
    Christoph Elsing, Christina Herrmann, Carla Verena Hannig, Wolfgang Stremmel, Dirk Jäger, Thomas Herrmann
    Oncology.2013; 85(5): 262.     CrossRef
  • 13,343 View
  • 68 Download
  • 15 Crossref
Close layer
Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases
Ji Yeon Kwon, Jina Yun, Han Jo Kim, Kyoung-Ha Kim, Se-Hyung Kim, Sang-Cheol Lee, Hyun Jung Kim, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Seong Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park
Cancer Res Treat. 2011;43(4):244-249.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.244
AbstractAbstract PDFPubReaderePub
PURPOSE
The prognosis of gastric cancer patients with bone marrow metastases is extremely poor. The current study was conducted to evaluate the clinical outcomes of advanced gastric cancer patients with bone marrow metastases.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 26 advanced gastric cancer patients with bone marrow metastases who were treated at Soonchunhyang University Hospital between September 1986 and February 2009.
RESULTS
The median age was 46 years (range, 24 to 61 years). All patients had poorly differentiated adenocarcinoma, including 17 signet ring cell carcinomas. The majority of the patients had thrombocytopenia, anemia, and elevated lactate dehydrogenase levels. Sixteen patients (61.5%) received palliative chemotherapy (median, 4 cycles; range, 1 to 13 cycles). The median overall survival after detection of bone marrow metastases for the cohort of patients was 37 days (95% confidence interval, 12.5 to 61.5 days). The median overall survival after detection of bone marrow involvement was 11 days in the best supportive care group (range, 2 to 34 days) and 121 days (range, 3 to 383 days) in the palliative chemotherapy group (p<0.001). The causes of death were tumor progression (11 patients, 45%), brain hemorrhage (6 patients, 25%), infection (5 patients, 21%), and disseminated intravascular coagulation (1 patient, 4%). There were no chemotherapy-related deaths.
CONCLUSION
Palliative chemotherapy could be considered in advanced gastric cancer patients with bone marrow metastases as a treatment option.

Citations

Citations to this article as recorded by  
  • Long-term survival of a patient with gastric cancer with bone marrow metastasis receiving S-1 plus oxaliplatin beyond three years: a case report and literature review
    Hirotaka Suto, Yumiko Inui, Atsuo Okamura
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Comprehensive review of solid tumor bone marrow metastasis
    Lanxin Zhang, Fengxi Chen, Lingzhi Xu, Ning Li, Qiping Zhuo, Yijin Guo, Xueqing Wang, Meijie Wen, Zuowei Zhao, Man Li
    Critical Reviews in Oncology/Hematology.2024; 194: 104248.     CrossRef
  • Mechanism and clinical progression of solid tumors bone marrow metastasis
    Ruohan Yang, Lin Jia, Jiuwei Cui
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and MET Abnormalities
    Wen Ye, Liping He, Lei Su, Zhousan Zheng, Meilin Ding, Sheng Ye
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Bone Metastasis From Gastric Adenocarcinoma—What Are the Risk Factors and Associated Survival? A Large Comprehensive Population-Based Cohort Study
    Lei Huang, Yajie Zhao, Yan Shi, Weiguo Hu, Jun Zhang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Gastric Cancer With Multiple Bone Metastases: An Uncommon Primary Presentation
    João Barbosa-Martins, Salomé Marques, Olinda Miranda, Bárbara Lima, Jorge Cotter
    Cureus.2022;[Epub]     CrossRef
  • Docetaxel and Fluorouracil as First-Line Therapy for Gastric Cancer with Bone Marrow Metastasis and Disseminated Intravascular Coagulation
    Zhai Xiaohui, Li Shanshan, Cao Taiyuan, Du Ge, Yu Hongen, Shi Lishuo, Lin Xiaoru, Hong Wanjia, Xiao Jian
    Future Oncology.2022; 18(35): 3875.     CrossRef
  • The influence of serum sodium concentration on prognosis in patients with urothelial carcinoma treated by radical cystectomy
    Yan Zhang, Zuojun Wang, Xue Yang, Qingchun Zhao, Long He
    Medicine.2022; 101(52): e31973.     CrossRef
  • Access to Palliative Care Services and Clinical Outcomes of Patients With Solid Malignancy-Associated Myelophthisis in a Resource-Limited Setting
    Cesar Vargas-Serafin, Aldo A. Acosta-Medina, Kevin Teran-De-la-Sancha, Jesus Delgado-de-la-Mora, María T. Bourlon, Christianne Bourlon
    American Journal of Hospice and Palliative Medicine®.2021; 38(8): 932.     CrossRef
  • Disseminated Bone Marrow Carcinomatosis Due to Malignant Melanoma of Unknown Primary Origin
    Kotaro Matsumoto, Kentaro Kikuchi, Tomohiro Kikuyama, Go Saito, Takako Adachi, Ayako Watanabe, Hiromichi Tsunashima, Takayuki Tsujikawa, Ken Sato, Shinpei Doi
    Internal Medicine.2021; 60(21): 3469.     CrossRef
  • Survival Outcomes and Treatment Decision by Human Papillomavirus Status Among Patients With Stage IVC Head and Neck Squamous Cell Carcinoma
    Ping Zhou, Yi-Feng Yu, Chen-Lu Lian, Jun Wang, Ren-Gong Zhuo, San-Gang Wu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Gastric Signet Ring Cell Carcinoma with Metastasis to the Bone and Bone Marrow in a Patient with 12-Year-Disease-Free Interval and Unusually Long Survival Time
    Hyung Woo Kim, Mi Jin Gu, Jong Ho Lee
    Laboratory Medicine Online.2021; 11(4): 305.     CrossRef
  • Signet-ring cells in the bone marrow as an indication of cryptic metastasis of breast carcinoma
    Shuang Ma, Bruce D. Leckey Jr, Wan-Lin Zhang, Hong-Tao Xu, Lian-He Yang, Endi Wang
    Medicine.2019; 98(11): e14883.     CrossRef
  • Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study
    Giovanni Fucà, Luigi Mariani, Salvatore Lo Vullo, Giulia Galli, Rossana Berardi, Massimo Di Nicola, Claudio Vernieri, Daniele Morelli, Katia Dotti, Ilaria Fiordoliva, Silvia Rinaldi, Cecilia Gavazzi, Filippo Pietrantonio, Marco Platania, Filippo de Braud
    Scientific Reports.2019;[Epub]     CrossRef
  • Malignant Pleural Mesothelioma with Bone Marrow Metastases
    Hiroaki Ihara, Norihiro Harada, Naoko Shimada, Koichiro Kanamori, Takuo Hayashi, Toshimasa Uekusa, Kazuhisa Takahashi
    Internal Medicine.2018; 57(17): 2541.     CrossRef
  • An unusual hematological presentation of gastric adenocarcinoma
    Hendra Koncoro, Eddy Setijoso, Findy Prasetiawaty, Maisie ME Johan, Renaningtyas Tambun
    Gastroenterology & Hepatology: Open Access.2018;[Epub]     CrossRef
  • Clinical outcome of 30 patients with bone marrow metastases
    Min Hang Zhou, Zhi Hong Wang, Hong Wei Zhou, Mo Liu, Yong Jian Gu, Jun Zhong Sun
    Journal of Cancer Research and Therapeutics.2018; 14(Suppl 2): S512.     CrossRef
  • Recurrent gastric cancer metastasizing to the bone marrow: A case report of a rare presentation
    Ernest Fonocho, Nail Aydin, Srini Reddy, Subhasis Misra
    International Journal of Surgery Case Reports.2017; 37: 165.     CrossRef
  • Clinical Outcomes of Endoscopic Hemostasis for Bleeding in Patients with Unresectable Advanced Gastric Cancer
    In Ji Song, Hyun Ju Kim, Ji Ae Lee, Jun Chul Park, Sung Kwan Shin, Sang Kil Lee, Yong Chan Lee, Hyunsoo Chung
    Journal of Gastric Cancer.2017; 17(4): 374.     CrossRef
  • Generalized high bone mineral density on bone density scanning: a case of gastric carcinoma with bone metastasis
    Pianpian Fan, Qin Wang, Chunyan Lu, Decai Chen
    Postgraduate Medicine.2017; 129(2): 299.     CrossRef
  • A case of disseminated carcinomatosis of the bone marrow originating from gastric cancer 3 years after intraperitoneal chemotherapy against peritoneal carcinomatosis
    Takayuki Okuno, Hironori Yamaguchi, Joji Kitayama, Hironori Ishigami, Takeshi Nishikawa, Junichiro Tanaka, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Hiroaki Nozawa, Kazushige Kawai, Shinsuke Kazama, Soichiro Ishihara, Eiji Sunami, Toshiaki Watan
    World Journal of Surgical Oncology.2016;[Epub]     CrossRef
  • Pathological findings in a case of bone marrow carcinosis due to gastric cancer complicated by disseminated intravascular coagulation and thrombotic microangiopathy
    Yoshinobu Seki, Kunihiko Wakaki
    International Journal of Hematology.2016; 104(4): 506.     CrossRef
  • Endoscopic Management of Tumor Bleeding from Inoperable Gastric Cancer
    Young-Il Kim, Il Ju Choi
    Clinical Endoscopy.2015; 48(2): 121.     CrossRef
  • An Unusual Case of Gastric Cancer with Bone Marrow Metastases and Embolic Phenomena as Initial Presentation
    Harjot Kaur, Appalanaidu Sasapu, Jeanette Ramos, Rangaswamy Govindarajan
    Journal of Gastrointestinal Cancer.2015; 46(4): 413.     CrossRef
  • Development and Validation of a Prognostic Score to Predict Survival in Adult Patients With Solid Tumors and Bone Marrow Metastases
    Wen-Chi Chou, Kun-Yun Yeh, Meng-Ting Peng, Jen-Shi Chen, Hung-Ming Wang, Yung-Chang Lin, Chien-Ting Liu, Shau-Hsuan Li, Pei-Hung Chang, Cheng-Hsu Wang, Ping-Tsung Chen, Yu-Shin Hung, Chang-Hsien Lu
    Medicine.2015; 94(23): e966.     CrossRef
  • Her-2 Positive Gastric Cancer Presented with Thrombocytopenia and Skin Involvement: A Case Report
    Deniz Arslan, Mukremin Uysal, Ali Murat Tatlı, Seyda Gunduz, Sema Sezgin Goksu, Cumhur İbrahim Başsorgun, Hasan Senol Coskun, Hakan Bozcuk, Burhan Savaş
    Case Reports in Oncological Medicine.2014; 2014: 1.     CrossRef
  • Gastric Carcinoma with Bone Marrow Metastasis: A Case Series
    Ahmet Şiyar Ekinci, Öznur Bal, Tahsin Özatlı, İbrahim Türker, Onur Eşbah, Ayşe Demirci, Burçin Budakoğlu, Ülkü Yalçıntaş Arslan, Emrah Eraslan, Berna Öksüzoğlu
    Journal of Gastric Cancer.2014; 14(1): 54.     CrossRef
  • Gastric cancer with initial bone metastasis: A distinct group of diseases with poor prognosis
    Yu Jung Kim, Se Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee
    European Journal of Cancer.2014; 50(16): 2810.     CrossRef
  • Methylated TIMP-3 DNA in Body Fluids Is an Independent Prognostic Factor for Gastric Cancer
    Jiang-Liu Yu, Ping Lv, Jing Han, Xin Zhu, Lian-Lian Hong, Wang-Yu Zhu, Xin-Bao Wang, Yi-Chen Wu, Pei Li, Zhi-Qiang Ling
    Archives of Pathology & Laboratory Medicine.2014; 138(11): 1466.     CrossRef
  • Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow Metastases
    Yu-Shin Hung, Wen-Chi Chou, Tai-Di Chen, Tse-Ching Chen, Po-Nan Wang, Hung Chang, Hung-Chih Hsu, Wen-Chi Shen, Wei-Hong Cheng, Jen-Shi Chen
    Asian Pacific Journal of Cancer Prevention.2014; 15(1): 61.     CrossRef
  • Preoperative serum pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen level predicts postoperative distant metastasis in patients with non-small-cell lung cancer†
    Yumi Tanaka, Tatsuya Yoshimasu, Shoji Oura, Yoshimitsu Hirai, Mitsumasa Kawago, Masako Ikeda, Yoshitaka Okamura
    European Journal of Cardio-Thoracic Surgery.2013; 44(3): 539.     CrossRef
  • 12,653 View
  • 104 Download
  • 31 Crossref
Close layer
Expression of BamHI-A Rightward Transcripts in Epstein-Barr Virus-Associated Gastric Cancers
Bo-Gun Jang, Eun Ji Jung, Woo Ho Kim
Cancer Res Treat. 2011;43(4):250-254.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.250
AbstractAbstract PDFPubReaderePub
PURPOSE
About 10% of all gastric cancers (GCs) are Epstein-Barr virus (EBV)-associated. However, the oncogene of EBV in gastric carcinogenesis has not yet been established. In the present study, we investigated the virus-derived transcripts in the EBV-infected GC cell line to explore the viral oncogene of EBV-positive GCs.
MATERIALS AND METHODS
We used the SNU719 cell line, a naturally derived EBV-infected GC cell line. The individual expressed sequence tags from the cDNA libraries of SNU719 were searched against the mRNA subset extracted from the GenBank data base. Sequence reaction was carried out for the EBV-associated clones. Reverse transcription-polymerase chain reaction was performed after cells were partitioned into nuclear and cytoplasmic fractions.
RESULTS
Using bioinformatic tools, we selected 13 EBV-associated clones from cDNA libraries of SNU719. By sequencing analysis, we revealed that they were all associated with RPMS1, one of the BamHI-A rightward transcripts (BART) of EBV. Some BART cDNAs such as RPMS1 and A73 are known to be translated into protein in vitro, and have been shown to have some biochemical functions relevant to tumorigenesis. But, presently, the BART transcripts were expressed only in the nucleus and not in the cytoplasm, arguing against their role as messenger RNAs. Some other BART transcripts expressed in GCs (BARF0, CST, vIL, BARF1, BLLF1, and BcLF1) were also extensively detected in the nucleus.
CONCLUSION
BART transcripts are the predominant viral transcripts expressed in EBV-associated GCs, and they are located only in the nucleus. Therefore, it seems less likely that BART transcripts produce functional proteins to play a role in carcinogenesis of EBV-associated GCs.

Citations

Citations to this article as recorded by  
  • EBV DNA methylation profiles and its application in distinguishing nasopharyngeal carcinoma and nasal NK/T-cell lymphoma
    Cao-Li Tang, Xi-Zhao Li, Ting Zhou, Chang-Mi Deng, Cheng-Tao Jiang, Yu-Meng Zhang, Ying Liao, Tong-Min Wang, Yong-Qiao He, Wen-Qiong Xue, Wei-Hua Jia, Xiao-Hui Zheng
    Clinical Epigenetics.2024;[Epub]     CrossRef
  • Long non-coding RNAs in Epstein–Barr virus-related cancer
    Yitong Liu, Zhizhong Hu, Yang Zhang, Chengkun Wang
    Cancer Cell International.2021;[Epub]     CrossRef
  • Epstein–Barr virus-associated gastric cancer: A distinct subtype
    Jing Yang, Zhifeng Liu, Bin Zeng, Guangsheng Hu, Runliang Gan
    Cancer Letters.2020; 495: 191.     CrossRef
  • Role of BamHI-A Rightward Frame 1 in Epstein–Barr Virus-Associated Epithelial Malignancies
    Rancés Blanco, Francisco Aguayo
    Biology.2020; 9(12): 461.     CrossRef
  • Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy
    MAMTA KALRA, ULRIKE GERDEMANN, JESSICA D. LUU, MINTHRAN C. NGO, ANN M. LEEN, CHRYSTAL U. LOUIS, CLIONA M. ROONEY, STEPHEN GOTTSCHALK
    Cytotherapy.2019; 21(2): 212.     CrossRef
  • Identification of virus-encoded circular RNA
    Jun-ting Huang, Jian-ning Chen, Li-ping Gong, Yuan-hua Bi, Jing Liang, Lu Zhou, Dan He, Chun-kui Shao
    Virology.2019; 529: 144.     CrossRef
  • DNA Methylation Pattern of Early Genes of Epstein Barr Virus Associated With Gastric Carcinoma in Group of Iraqi Patients
    Hiba Sabah Jasim
    Journal of Pure and Applied Microbiology.2019; 13(1): 441.     CrossRef
  • Conservation and polymorphism of EBV RPMS1 gene in EBV-associated tumors and healthy individuals from endemic and non-endemic nasopharyngeal carcinoma areas in China
    Shuo Wu, Wen Liu, Hong Li, Zhenzhen Zhao, Yang Yang, Hua Xiao, Yingying Song, Bing Luo
    Virus Research.2018; 250: 75.     CrossRef
  • The Methylation Status and Expression of Epstein-Barr Virus Early Genes BARF1 and BHRF1 in Epstein-Barr Virus-Associated Gastric Carcinomas
    Jing Li, Wen Liu, Kui Che, Yan Zhang, Zhenzhen Zhao, Bing Luo
    Gastroenterology Research and Practice.2017; 2017: 1.     CrossRef
  • Genetics and Molecular Biology of Epstein-Barr Virus-Encoded BART MicroRNA: A Paradigm for Viral Modulation of Host Immune Response Genes and Genome Stability
    David H. Dreyfus
    Journal of Immunology Research.2017; 2017: 1.     CrossRef
  • The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma
    Chi Man Tsang, Sai Wah Tsao
    Virologica Sinica.2015; 30(2): 107.     CrossRef
  • Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma
    Francesco Abate, Maria Raffaella Ambrosio, Lucia Mundo, Maria Antonella Laginestra, Fabio Fuligni, Maura Rossi, Sakellarios Zairis, Sara Gazaneo, Giulia De Falco, Stefano Lazzi, Cristiana Bellan, Bruno Jim Rocca, Teresa Amato, Elena Marasco, Maryam Etebar
    PLOS Pathogens.2015; 11(10): e1005158.     CrossRef
  • Differences in Gastric Carcinoma Microenvironment Stratify According to EBV Infection Intensity: Implications for Possible Immune Adjuvant Therapy
    Michael J. Strong, Guorong Xu, Joseph Coco, Carl Baribault, Dass S. Vinay, Michelle R. Lacey, Amy L. Strong, Teresa A. Lehman, Michael B. Seddon, Zhen Lin, Monica Concha, Melody Baddoo, MaryBeth Ferris, Kenneth F. Swan, Deborah E. Sullivan, Matthew E. Bur
    PLoS Pathogens.2013; 9(5): e1003341.     CrossRef
  • 11,258 View
  • 68 Download
  • 13 Crossref
Close layer
Case Reports
Cyclosporine in Relapsed Subcutaneous Panniculitis-like T-Cell Lymphoma after Autologous Hematopoietic Stem Cell Transplantation
Hye Ryun Jung, So Yeon Yun, Jun Hyeok Choi, Sung Hwa Bae, Hun-Mo Ryoo, Yoon-Seup Kum
Cancer Res Treat. 2011;43(4):255-259.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.255
AbstractAbstract PDFPubReaderePub
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare T-cell lymphoma characterized by involvement of the subcutaneous tissue of neoplastic T lymphocytes. SPTCL with hemophagocytic syndrome (HPS) is associated with an aggressive clinical course and treatment of SPTCL with HPS is not well established. Cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy is not successful in most patients suffering from SPTCL with HPS. The role of high dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT) remains controversial. We report a case of relapsed SPTCL after CHOP chemotherapy and salvage chemotherapy followed by autologous HSCT, which had rapid improvement within weeks after cyclosporine and prednisolone. Immunosuppressive therapy may be an important and successful treatment option in SPTCL patients, even though they may have clinically aggressive disease.

Citations

Citations to this article as recorded by  
  • Rare Cutaneous T-Cell Lymphomas
    Fabiana Damasco, Oleg E. Akilov
    Hematology/Oncology Clinics of North America.2019; 33(1): 135.     CrossRef
  • Hematopoietic stem cell transplantation for subcutaneous panniculitis-like T-cell lymphoma: single center experience in an Asian population
    Ting-An Lin, Ching-Fen Yang, Yao-Chung Liu, Jin-Hwang Liu, Tzeon-jye Chiou, Liang-Tsai Hsiao, Hsiu-Ju Yen, Chia-Jen Liu, Hao-Yuan Wang, Po-Shen Ko, Sheng-Hsuan Chien, Jyh-Pyng Gau
    International Journal of Hematology.2019; 109(2): 187.     CrossRef
  • A Systematic Approach to the Cutaneous Lymphoid Infiltrates: A Clinical, Morphologic, and Immunophenotypic Evaluation
    Alejandro A. Gru, Chauncey McHargue, Andrea L. Salavaggione
    Archives of Pathology & Laboratory Medicine.2019; 143(8): 958.     CrossRef
  • Subcutaneous panniculitis-like T-cell lymphoma: Clinical features, therapeutic approach, and outcome in a case series of 16 patients
    Ingrid López-Lerma, Yeray Peñate, Fernando Gallardo, Rosa M. Martí, Josune Mitxelena, Isabel Bielsa, Virginia Velasco-Tamariz, Juan I. Yanguas-Bayona, Pedro Sánchez-Sambucety, Vicente García-Patos, Pablo L. Ortiz-Romero, Ramón M. Pujol, Teresa Estrach
    Journal of the American Academy of Dermatology.2018; 79(5): 892.     CrossRef
  • Uncommon Variants of T-Cell Lymphomas
    Neha Mehta-Shah, Steven Horwitz
    Hematology/Oncology Clinics of North America.2017; 31(2): 285.     CrossRef
  • Relapsed and refractory subcutaneous panniculitis-like T-cell lymphoma with excellent response to cyclosporine: a case report and literature review
    Chi-Ching Chen, Chieh-Lin Teng, Su-Peng Yeh
    Annals of Hematology.2016; 95(5): 837.     CrossRef
  • Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides
    Meenal Kheterpal, Neha Mehta-Shah, Pooja Virmani, Patricia L. Myskowski, Alison Moskowitz, Steven M. Horwitz
    Current Hematologic Malignancy Reports.2016; 11(3): 224.     CrossRef
  • Zebras and hen's teeth: recognition and management of rare T and NK lymphomas
    Neha Mehta–Shah, Steven Horwitz
    Hematology.2015; 2015(1): 545.     CrossRef
  • Cyclosporine A as a Primary Treatment for Panniculitis-like T Cell Lymphoma: A Case with a Long-Term Remission
    Won Sup Lee, Ji-Hyen Hwang, Moon Jin Kim, Se-Il Go, Anna Lee, Haa-Na Song, Min Jeong Lee, Myung Hee Kang, Hoon-Gu Kim, Jeong-Hee Lee
    Cancer Research and Treatment.2014; 46(3): 312.     CrossRef
  • 9,992 View
  • 93 Download
  • 9 Crossref
Close layer
Fatal Ifosfamide-Induced Metabolic Encephalopathy in Patients with Recurrent Epithelial Ovarian Cancer: Report of Two Cases
You-Jung Shin, Ji-Young Kim, Jei-Won Moon, Rae-Mi You, Jeong-Yeol Park, Joo-Hyun Nam
Cancer Res Treat. 2011;43(4):260-263.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.260
AbstractAbstract PDFPubReaderePub
Central nervous system (CNS) toxicity has been reported in approximately 10-30% of patients receiving intravenous infusions of ifosfamide. Encephalopathy is a rare but serious CNS adverse reaction in these patients, and although usually transient and reversible, may cause persistent neurological dysfunction or death. Clinical features range from fatigue and confusion to coma and death. Although methylene blue can be used to treat ifosfamide-induced neurotoxicity, including encephalopathy, its mechanism of action remains poorly defined. We describe here two patients with recurrent epithelial ovarian cancer who experienced fatal encephalopathy following ifosfamide/mesna treatment.

Citations

Citations to this article as recorded by  
  • Rare Delayed Ifosfamide Encephalopathy: A Case Report of Chemotherapeutic Neurotoxicity
    Ambika Menon, Chidiebele A. Enunwa, William L. Read, Kyle P. James
    Case Reports in Oncology.2024; 17(1): 202.     CrossRef
  • Potential of Cytochrome P450, a Family of Xenobiotic Metabolizing Enzymes, in Cancer Therapy
    Ragini D. Singh, Avadhesh Avadhesh, Gaurav Sharma, Sagar Dholariya, Rima B. Shah, Bela Goyal, Subash Chandra Gupta
    Antioxidants & Redox Signaling.2023; 38(10-12): 853.     CrossRef
  • Ifosfamide - History, efficacy, toxicity and encephalopathy
    Jeffrey R. Idle, Diren Beyoğlu
    Pharmacology & Therapeutics.2023; 243: 108366.     CrossRef
  • A Case of Encephalopathy Caused by Drug Interaction between Ifosfamide and Aprepitant
    Tomomi Sano, Nokitaka Setsu, Eisuke Kobayashi, Akira Kawai
    YAKUGAKU ZASSHI.2023; 143(6): 541.     CrossRef
  • Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies
    Ali Zarrabi, David Perrin, Mahboubeh Kavoosi, Micah Sommer, Serap Sezen, Parvaneh Mehrbod, Bhavya Bhushan, Filip Machaj, Jakub Rosik, Philip Kawalec, Saba Afifi, Seyed Mohammadreza Bolandi, Peiman Koleini, Mohsen Taheri, Tayyebeh Madrakian, Marek J. Łos,
    Cancers.2023; 15(21): 5269.     CrossRef
  • Ifosfamide-induced Encephalopathy With Rapid Response to Thiamine: A Pediatric Case
    Eren Müngen, İnci Yaman Bajin, Sibel Öz, Ceren Günbey, Banu Anlar, Burca Aydin
    Journal of Pediatric Hematology/Oncology.2022; 44(7): 402.     CrossRef
  • Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?
    Halima Abahssain, Badreddine Moukafih, Hajar Essangri, Hind Mrabti, Bouchra Meddah, Fadila Guessous, Fatima Zahra Fadhil, Amine Souadka, Hassan Errihani
    Journal of Oncology Pharmacy Practice.2021; 27(1): 143.     CrossRef
  • Effect of Berberis vulgaris L. root extract on ifosfamide-induced in vivo toxicity and in vitro cytotoxicity
    Shazia Ilyas, Raheela Tabasum, Ali Iftikhar, Mamoona Nazir, Amina Hussain, Aroosha Hussain, Muhammad Sajjad Ali, Farooq Saleem, Uzma Saleem, Matheus Froeyen, Iskandar Abdullah, Muhammad Usman Mirza, Sarfraz Ahmad
    Scientific Reports.2021;[Epub]     CrossRef
  • Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer
    Eda Ataseven, Şebnem Önen Göktepe, Mehmet Kantar
    Journal of Oncology Pharmacy Practice.2021; 27(8): 2018.     CrossRef
  • Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies
    Claudia Pellacani, Georgios Eleftheriou
    Advances in Medical Sciences.2020; 65(2): 265.     CrossRef
  • Delayed Ifosfamide Neurotoxicity
    Jill Yeager, Alina Basnet
    American Journal of Therapeutics.2020; 27(6): e613.     CrossRef
  • Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy
    Aaron M. Gusdon, Rachna Malani, Xi Chen
    Journal of Clinical Neurophysiology.2019; 36(2): 150.     CrossRef
  • Incidence et facteurs de risque de l’encéphalopathie à l’ifosfamide chez les patients suivis pour un sarcome
    Natacha Stern, Ilyes Sakji, Anne-Sophie Defachelles, Cyril Lervat, Thomas Ryckewaert, Guillaume Marliot, Charlotte Peugniez, Dominique Deplanque, Nicolas Penel
    Bulletin du Cancer.2017; 104(3): 208.     CrossRef
  • Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis
    Yin Lo, Li-Jiuan Shen, Wen-Hwei Chen, Yaa-Hui Dong, Fe-Lin Lin Wu
    Journal of the Formosan Medical Association.2016; 115(9): 744.     CrossRef
  • The Neurotoxicity and Pharmacokinetics of Oral Ifosfamide
    Martin S. Highley, Guido Momerency, Diane Sawyers, Ernst A. De Bruijn, Hans Prenen, Gunther Guetens, Gert De Boeck, Allan T. Van Oosterom, Janine L. Mansi, Peter R. Blake, Tim Mant, Robert A.A. Maes , Peter G. Harper
    Journal of Analytical Oncology.2015;[Epub]     CrossRef
  • Ifosfamide related encephalopathy: The need for a timely EEG evaluation
    Anteneh M. Feyissa, Sudhakar Tummala
    Journal of the Neurological Sciences.2014; 336(1-2): 109.     CrossRef
  • PharmGKB summary
    Daniella Lowenberg, Caroline F. Thorn, Zeruesenay Desta, David A. Flockhart, Russ B. Altman, Teri E. Klein
    Pharmacogenetics and Genomics.2014; 24(2): 133.     CrossRef
  • Two Cases of Fatal Encephalopathy Related to Ifosfamide: An Adverse Role of Aprepitant
    Alice Séjourné, Sabine Noal, Mathieu Boone, Céline Bihan, Marion Sassier, Michel Andrejak, Bruno Chauffert
    Case Reports in Oncology.2014; 7(3): 669.     CrossRef
  • 13,799 View
  • 110 Download
  • 18 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP